GLAXOSMITHKLINE PLC Form 6-K April 19, 2017

#### FORM 6-K

#### SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending 19 April 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

	Details of PDMR/person closely associa Name	Ms E W	almsley
))	Position/status	Chief Ex	ecutive Officer
)	Initial notification/ amendment	Initial no	otification
•	Details of the issuer, emission allowance auctioneer or auction monitor	e market p	participant, auction platform,
)	Name	GlaxoSn	nithKline plc
)	LEI		HZTVUYLO1D793
	Details of the transaction(s): section to b	·	•••
•	(ii) each type of transaction; (iii) each da has been conducted		
		-	v shares of 25 pence each
)	Description of the financial instrument	('Ordina	ry Shares')
		ISIN: GI	B0009252882
)	Nature of the transaction	Shares for	in notional interest in Ordinary ollowing the re-investment of s paid to shareholders on 13 April
,	Nature of the transaction		Ordinary Shares held in the
,		Compan	Ordinary Shares held in the y's 2009 Deferred Annual Bonus
,		Compan Plan.	y's 2009 Deferred Annual Bonus
,		Compan Plan. Price(s)	y's 2009 Deferred Annual Bonus Volume(s)
,		Compan Plan.	y's 2009 Deferred Annual Bonus Volume(s)
		Compan Plan. Price(s)	y's 2009 Deferred Annual Bonus Volume(s)
		Compan Plan. Price(s) £16.47	y's 2009 Deferred Annual Bonus Volume(s) 82.730 (personal contribution)
		Compan Plan. Price(s) £16.47 £16.47	y's 2009 Deferred Annual Bonus Volume(s) 82.730 (personal contribution) 204.873 (personal contribution)

£16.47	223.045 (personal contribution)
£16.47	82.730 (matching shares)
£16.47	204.873 (matching shares)
£16.47	223.059 (matching shares)
£16.47	82.730 (matching shares)
£16.47	204.858 (matching shares)
£16.47	223.045 (matching shares)

d)	Aggregated information Aggregated volume Price	2,042.590 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

<sup>1.</sup> Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr R G Connor		
<i>a)</i>	Name			
b)	Position/status	President, Global Manufacturing &		
,	<b>.</b>	Supply		
c)	Initial notification/	Initial notification		
0)	amendment			
2.	Details of the issuer, emission allowance	market participant, auction platform,		
۷.	auctioneer or auction monitor			
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000HZTVUYLO1D793		
	Details of the transaction(s): section to b	e repeated for (i) each type of instrument;		
3.		te; and (iv) each place where transaction(s)		
	has been conducted			
		Ordinary shares of 25 pence each		
		('Ordinary Shares')		
a)	Description of the financial instrument	(Ordinary Shares)		
		ISIN: GB0009252882		
		Increase in notional interest in Ordinary		
		Shares following the re-investment of		
b)	Nature of the transaction	dividends paid to shareholders on 13 April		
,		2017 on Ordinary Shares held in the		
		Company's 2009 Deferred Annual Bonus		
		Plan.		
		Price(s) Volume(s)		
		£16.47 60.585 (personal contribution)		
		£16.47 139.194 (personal contribution)		
		_		

£16.47	116.145 (personal contribution)
£16.47	60.585 (personal contribution)
£16.47	116.131 (personal contribution)
£16.47	60.585 (matching shares)
£16.47	139.194 (matching shares)
£16.47	116.145 (matching shares)
£16.47	60.585 (matching shares)
£16.47	116.131 (personal contribution)

	Aggregated information	
d)		985.280
	Aggregated volume Price	£16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr L Debruyne	
b)	Position/status	President, Global Vaccines	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance auctioneer or auction monitor	e market participant, auction platform,	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to b (ii) each type of transaction; (iii) each da transaction(s) has been conducted	e repeated for (i) each type of instrument; ate; and (iv) each place where	
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')	
b)	Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s)	
		£16.47 195.213 (personal contribution)	

		£16.47	195.199 (personal contribution)
		£16.47	195.213 (matching shares)
		£16.47	195.199 (matching shares)
	Aggregated information		
d)	Aggregated volume Price	780.824 £16.47	
e)	Date of the transaction	2017-04	l-18
f)	Place of the transaction	n/a	
	Details of PDMR/person closely associa		
	Name	Mr S Di	0
b)	Position/status	Chief Fin	nancial Officer
c)	Initial notification/ amendment	Initial no	otification
2.	Details of the issuer, emission allowance auctioneer or auction monitor	e market p	participant, auction platform,
a)	Name	GlaxoSn	nithKline plc
b)	LEI		HZTVUŶLO1D793
	Details of the transaction(s): section to b	e repeated	d for (i) each type of instrument;
3.	(ii) each type of transaction; (iii) each da has been conducted	-	•
		Ordinary	v shares of 25 pence each
a)	Description of the financial instrument	-	ry Shares')
			80009252882
			in notional interest in Ordinary
			ollowing the re-investment of
b)	Nature of the transaction		s paid to shareholders on 13 April
			Ordinary Shares held in the y's 2009 Deferred Annual Bonus
		Plan.	y s 2009 Deferred Affilial Bollus
			Volume(s)
		£16.47	115.556 (personal contribution)
		£16.47	270.551 (personal contribution)
		£16.47	202.642 personal contribution)
		£16.47	115.540 (personal contribution)
		£16.47	270.537 (personal contribution)
	<b>D</b> rive(a) and volume(a)	£16.47	202.642 (personal contribution)

c) Price(s) and volume(s)

£16.47	115.556 (matching shares)
£16.47	270.551 (matching shares)
£16.47	202.642 (matching shares)
£16.47	115.540 (matching shares)
£16.47	270.537 (matching shares)
£16.47	202.642 (matching shares)

	Aggregated information	
d)		2,354.936
	Aggregated volume Price	£16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

1.	Details of I Diving person closely associa		
a)	Name	Mr N Hi	rons
b)	Position/status	SVP, Gl	obal Ethics & Compliance
c)	Initial notification/ amendment	Initial no	otification
2.	Details of the issuer, emission allowance auctioneer or auction monitor	e market p	participant, auction platform,
a)	Name	GlaxoSn	nithKline plc
b)	LEI	5493000	HZTVUYLO1D793
,	Details of the transaction(s): section to b	e repeated	d for (i) each type of instrument;
3.	(ii) each type of transaction; (iii) each da has been conducted		
		Ordinary	v shares of 25 pence each
a)	Description of the financial instrument	-	ry Shares')
b)	Nature of the transaction	Increase Shares for dividend 2017 on Compan Plan. Price(s)	B0009252882 in notional interest in Ordinary ollowing the re-investment of ls paid to shareholders on 13 April Ordinary Shares held in the y's 2009 Deferred Annual Bonus Volume(s) 42.420 (personal contribution)
		£16.47	100.034 (personal contribution)
		£16.47	73.412 (personal contribution)
		£16.47	42.420 (personal contribution)

		£16.47	100.034 (personal contribution)
		£16.47	73.398 (personal contribution)
		£16.47	42.420 (matching shares)
		£16.47	100.034 (matching shares)
		£16.47	73.412 (matching shares)
		£16.47	42.420 (matching shares)
		£16.47	100.034 (matching shares)
		£16.47	73.398 (matching shares)
	A		
d)	Aggregated information	863.436	
u)	Aggregated volume Price	£16.47	
e)	Date of the transaction	2017-04	-18
f)	Place of the transaction	n/a	
a)	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance	Mr S A l Presiden Initial no	Hussain t, Global Pharmaceuticals otification
a)	auctioneer or auction monitor Name	GlaxoSn	nithKline plc
	LEI		HZTVUYLO1D793
3.	Details of the transaction(s): section to b (ii) each type of transaction; (iii) each da has been conducted	-	•••
a)	Description of the financial instrument		y shares of 25 pence each ry Shares')
b)	Nature of the transaction	Increase Shares for dividend 2017 on Compan Plan.	B0009252882 in notional interest in Ordinary ollowing the re-investment of s paid to shareholders on 13 April Ordinary Shares held in the y's 2009 Deferred Annual Bonus Volume(s) 199.970 (personal contribution)

£16.47	236.389 (personal contribution)
£16.47	202.908 personal contribution)
£16.47	236.389 (personal contribution)
£16.47	202.894 (personal contribution)
£16.47	199.970 (matching shares)
£16.47	236.389 (matching shares)
£16.47	202.908 (matching shares)
£16.47	236.389 (matching shares)
£16.47	202.894 (matching shares)

d)	Aggregated information	2,157.100
- )	Aggregated volume Price	£16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associa	ted with them ('PCA')			
	Name	Mr B McNamara			
b)	Position/status	CEO, GSK Consumer Healthcare			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, emission allowance	e market participant, auction platform,			
	auctioneer or auction monitor	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~			
a)	Name	GlaxoSmithKline plc			
b)	LEI	5493000HZTVUYLO1D793			
	Details of the transaction(s): section to be repeated for (i) each type of instrument;				
3.	. (ii) each type of transaction; (iii) each date; and (iv) each place where				
	transaction(s) has been conducted				
		American Depositary Shares ('ADSs')			
a)	Description of the financial instrument				
		ISIN: US37733W1053			
		ISIN: US37733W1053 Increase in notional interest in ADSs			
		Increase in notional interest in ADSs			
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends			
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on			
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends			
,		Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.			
,	Nature of the transaction Price(s) and volume(s)	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009			
,		Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s)			

d)	Aggregated information	165.958	
(1)	Aggregated volume Price	\$41.81	
e)	Date of the transaction	2017-04	-18
f)	Place of the transaction	n/a	
	Details of PDMR/person closely associa Name	ted with t Mr D S I	
	Position/status		rategy Officer
c)	Initial notification/ amendment		otification
2.	Details of the issuer, emission allowance auctioneer or auction monitor	e market p	participant, auction platform,
	Name LEI		nithKline plc HZTVUYLO1D793
í	Details of the transaction(s): section to b (ii) each type of transaction; (iii) each da has been conducted	e repeated	d for (i) each type of instrument;
		Ordinary	v shares of 25 pence each
a)	Description of the financial instrument	('Ordinat	ry Shares')
b)	Nature of the transaction	Increase Shares for dividend 2017 on	B0009252882 in notional interest in Ordinary ollowing the re-investment of is paid to shareholders on 13 April Ordinary Shares held in the y's 2009 Deferred Annual Bonus
		Price(s)	Volume(s) 67.977 (personal contribution)
		£16.47	127.311 (personal contribution)
		£16.47	92.391 (personal contribution)
		£16.47	67.977 (personal contribution)
		£16.47	127.311 (personal contribution)
c)	Price(s) and volume(s)	£16.47	92.377 (personal contribution)
		£16.47	67.977 (matching shares)
		£16.47	127.311 (matching shares)
		£16.47	92.391 (matching shares)

	£16.47 67.977 (matching shares)		
	£16.47 127.311 (matching shares)		
	£16.47 92.377 (matching shares)		
Aggregated information	1,150.688		
d)	£16.47		
Aggregated volume Price			
e) Date of the transaction	2017-04-18		
f) Place of the transaction	n/a		
1. Details of PDMR/person closely assoc			
<ul><li>a) Name</li><li>b) Position/status</li></ul>	Ms C Thomas SVP, Human Resources		
c) initial notification/	Initial notification		
	amendment Details of the issuer, emission allowance market participant, auction platform		
<ul><li>auctioneer or auction monitor</li><li>a) Name</li></ul>	auctioneer or auction monitor		
b) LEI	5493000HZTVUYLO1D793		
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a) Description of the financial instrument ('Ordinary Shares')			
u) Description of the influence			
	ISIN: GB0009252882		
b) Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus		
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.		
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus		
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s)		
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £16.47 91.499 (personal contribution)		
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £16.47 91.499 (personal contribution) £16.47 186.252 (personal contribution)		

£16.47	139.061 (personal contribution)
£16.47	91.499 (matching shares)
£16.47	186.252 (matching shares)
£16.47	139.061 (matching shares)
£16.47	91.483 (matching shares)
£16.47	186.252 (matching shares)
£16.47	139.061 (matching shares)

d)	Aggregated information	1,667.216 £16.47
,	Aggregated volume Price	
e) f)	Date of the transaction Place of the transaction	2017-04-18 n/a

1. Details of PDMR/person closely associated with them ('PCA')

1.	Details of I Diving person closely associa	ted with them (TCA)
a)	Name	Mr P C Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance auctioneer or auction monitor	e market participant, auction platform,
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to b	e repeated for (i) each type of instrument; ate; and (iv) each place where transaction(s)
		Ordinary shares of 25 pence each
a)	Description of the financial instrument	('Ordinary Shares')
b)	Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £16.47 62.146 (personal contribution)

£16.47 113.955 (personal contribution)

		£16.47	87.545 (personal contribution)	
		£16.47	62.146 (matching shares)	
		£16.47	113.955 (matching shares)	
		£16.47	87.545 matching shares)	
d)	Aggregated information	527.292 £16.47		
u)	Aggregated volume Price	210.47		
e)	Date of the transaction	2017-04	-18	
f)	Place of the transaction	n/a		
1.	. Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Mr D E	Troy	
b)	Position/status	SVP & O	General Counsel	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer emission allowance market participant auction platform			
a)	Name GlaxoSmithKline plc			
b)	LEI		HZTVUYLO1D793	
	Details of the transaction(s): section to be repeated for (i) each type of instrument			
3.	<ul> <li>3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s has been conducted</li> </ul>			
American Depositary Shares ('ADSs')			n Depositary Shares ('ADSs')	
a) Description of the financial instrument				
	•	ISIN: US	\$37733W1053	
		Increase	in notional interest in ADSs	
		followin	g the re-investment of dividends	
b)	Nature of the transaction	paid to shareholders on 13 April 2017 on		
		ADSs he	eld in the Company's 2009	
		Deferred	l Annual Bonus Plan.	
		Price(s)	Volume(s)	
		\$41.81	47.220 (personal contribution)	
		\$41.81	106.319 (personal contribution)	
		\$41.81	88.057 (personal contribution)	
		\$41.81	47.220 (personal contribution)	
		\$41.81	106.319 (personal contribution)	

		\$41.81	88.044 (personal contribution)	
		\$41.81	47.220 (matching shares)	
		\$41.81	106.319 (matching shares)	
		\$41.81	88.057 (matching shares)	
		\$41.81	47.220 (matching shares)	
		\$41.81	106.319 (matching shares)	
		\$41.81	88.044 (matching shares)	
	Aggregated information			
d)	Aggregated volume Price	966.358 \$41.81		
e)	Date of the transaction	2017-04	-18	
f)	Place of the transaction	n/a		
1.	Details of PDMR/person closely associa	ted with t	hem ('PCA')	
a)	Name	Dr P J T Vallance		
b)	Position/status	President, R&D		
c)	Initial notification/ amendment	Initial notification		
2.	2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
	Name	GlaxoSmithKline plc 5493000HZTVUYLO1D793		
D)	LEI Details of the transaction(s): section to b			
3.	<ul><li>Details of the transaction(s): section to be repeated for (i) each type of instrument;</li><li>3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted</li></ul>			
		Ordinary	v shares of 25 pence each	
a)	Description of the financial instrument	('Ordina	ry Shares')	
		Increase Shares fo	B0009252882 in notional interest in Ordinary ollowing the re-investment of	
b)	Nature of the transaction	dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.		
			Volume(s)	
		£16.47	134.685 (personal contribution)	
		£16.47	219.092 (personal contribution)	

£16.47	151.043 (personal contribution)	)
--------	---------------------------------	---

£16.47	134.685	(personal	contribution)
--------	---------	-----------	---------------

- £16.47 219.092 (personal contribution)
- 151.043 (personal contribution) £16.47
- £16.47 134.685 (matching shares)
- £16.47 219.092 (matching shares)
- £16.47 151.043 (matching shares)
- £16.47 134.685 (matching shares)
- £16.47 219.092 (matching shares)
- £16.47 151.043 (matching shares)

d)	Aggregated information	2,019.280 £16.47	
,	Aggregated volume Price		
e)		2017-04-18	
f)	Place of the transaction	n/a	

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

> GlaxoSmithKline plc (Registrant)

Date: April 19, 2017

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on behalf of GlaxoSmithKline plc